Login to Your Account



EMCC Roundup

Detailed Phase II T-DM1 Breast Cancer Data Boost ImmunoGen

By Jennifer Boggs


Tuesday, September 27, 2011
ImmunoGen Inc. and partner Roche AG reported positive top-line data earlier this year from a Phase II trial testing T-DM1 in HER2-positive metastatic breast cancer patients, but observers had been waiting for the detailed progression-free survival (PFS) numbers. They got those figures Sunday during a presentation at the European Multidisciplinary Cancer Congress (EMCC) in Stockholm, Sweden.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription